Ceribell, Inc. (CBLL) stock
CBLLNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30150% above fair value
$26.35−1.45 (-5.22%)
Close on Nov 12, 2026Market cap $1.01BP/E –Yield –
Ceribell gross margin
Gross margin is gross profit as a percentage of revenue.
Ceribell's gross margin for the twelve months ending Jun 30, 2026 was 88.9%. For fiscal 2025 it was 87.9%, against 86.7% the year before.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 87.9% | +1.2 |
| FY2024 | Dec 31, 2024 | 86.7% | +2.3 |
| FY2023 | Dec 31, 2023 | 84.4% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 92.3% | +4.2 |
| Q1 FY2026 | Mar 31, 2026 | 87.3% | −0.6 |
| Q4 FY2025 | Dec 31, 2025 | 87.3% | −0.3 |
| Q3 FY2025 | Sep 30, 2025 | 88.3% | +1.0 |
| Q2 FY2025 | Jun 30, 2025 | 88.1% | +2.2 |
| Q1 FY2025 | Mar 31, 2025 | 87.9% | +2.2 |
| Q4 FY2024 | Dec 31, 2024 | 87.6% | +3.0 |
| Q3 FY2024 | Sep 30, 2024 | 87.3% | +3.5 |
| Q2 FY2024 | Jun 30, 2024 | 85.9% | – |
| Q1 FY2024 | Mar 31, 2024 | 85.7% | – |
| Q4 FY2023 | Dec 31, 2023 | 84.7% | – |
| Q3 FY2023 | Sep 30, 2023 | 83.8% | – |
See a number that looks wrong?